[go: up one dir, main page]

MA41377A - Gel intestinal de lévodopa et de carbidona et procédés d'utilisation - Google Patents

Gel intestinal de lévodopa et de carbidona et procédés d'utilisation

Info

Publication number
MA41377A
MA41377A MA041377A MA41377A MA41377A MA 41377 A MA41377 A MA 41377A MA 041377 A MA041377 A MA 041377A MA 41377 A MA41377 A MA 41377A MA 41377 A MA41377 A MA 41377A
Authority
MA
Morocco
Prior art keywords
carbidona
levodopa
procedures
intestinal gel
intestinal
Prior art date
Application number
MA041377A
Other languages
English (en)
Inventor
Rajkumar Conjeevaram
Alexandru Deac
Ye Huang
Sean E Mackey
Randy A Menges
Jayne B Zimmerman
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MA41377A publication Critical patent/MA41377A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physiology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
MA041377A 2015-01-20 2016-01-19 Gel intestinal de lévodopa et de carbidona et procédés d'utilisation MA41377A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562105565P 2015-01-20 2015-01-20
US201562272922P 2015-12-30 2015-12-30

Publications (1)

Publication Number Publication Date
MA41377A true MA41377A (fr) 2017-11-28

Family

ID=55410198

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041377A MA41377A (fr) 2015-01-20 2016-01-19 Gel intestinal de lévodopa et de carbidona et procédés d'utilisation

Country Status (16)

Country Link
US (3) US10117843B2 (fr)
EP (2) EP3247330A1 (fr)
JP (4) JP2018503686A (fr)
KR (1) KR20170103967A (fr)
CN (2) CN107427463A (fr)
AU (1) AU2016209420B2 (fr)
BR (1) BR112017015613B1 (fr)
CA (1) CA2974203A1 (fr)
IL (1) IL253487A0 (fr)
MA (1) MA41377A (fr)
MX (1) MX2017009325A (fr)
PH (1) PH12017501304A1 (fr)
RU (1) RU2017129375A (fr)
SG (1) SG11201705964YA (fr)
TW (1) TW201639556A (fr)
WO (1) WO2016118556A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102537018B1 (ko) 2014-10-21 2023-05-30 애브비 인코포레이티드 카르비도파 및 l-도파 프로드럭 및 파킨슨병을 치료하기 위한 이들의 용도
BR112017023674A2 (pt) 2015-05-06 2018-07-17 Synagile Corporation suspensões farmacêuticas contendo partículas de fármaco, dispositivos para sua administração, e métodos de seu uso
US20180021280A1 (en) * 2016-07-20 2018-01-25 Abbvie Inc. Levodopa and Carbidopa Intestinal Gel and Methods of Use
JP7314871B2 (ja) 2020-07-09 2023-07-26 新東工業株式会社 強度計測装置及び強度計測方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3132171A (en) 1962-06-18 1964-05-05 Strong Cobb Arner Inc 3, 4-diphosphatophenyl-alanine and process for making same
US4618484A (en) 1983-03-30 1986-10-21 Yale University Composition and method for treatment of melanomas
ES2070994T3 (es) 1989-04-20 1995-06-16 Zambon Spa Profarmaco de dopamina.
IT1255471B (it) 1992-07-30 1995-11-02 Zambon Spa Derivati di catecolammine,processo per la loro preparazione e composizioni farmaceutiche che li contengono
SE9203594D0 (sv) * 1992-11-30 1992-11-30 Christer Nystroem Laekemedel i dispersa system
US6365180B1 (en) 1998-01-20 2002-04-02 Glenn A. Meyer Oral liquid compositions
EP1596808A4 (fr) 2003-02-07 2007-04-04 Yissum Res Dev Co Derives d'amide l-dopa et utilisations de ceux-ci
MX2008015339A (es) * 2006-05-31 2008-12-16 Solvay Pharm Gmbh Administracion intestinal a largo plazo durante 24 horas de levodopa/carbidopa.
US20130253056A1 (en) 2009-05-19 2013-09-26 Neuroderm, Ltd. Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same
EP3777839A1 (fr) 2009-05-19 2021-02-17 Neuroderm Ltd Compositions pour administration continue d'inhibiteurs de la dopa décarboxylase
EP2515876B1 (fr) 2009-11-09 2016-01-06 XenoPort, Inc. Compositions pharmaceutiques et formes galéniques orales d'un promédicament de lévodopa et procédés d'utilisation
SI2640358T1 (en) * 2010-11-15 2018-05-31 Neuroderm Ltd. Continuous administration of L-dopa, dopamine decarboxylase inhibitors, catechol-O-methyl transferase inhibitors, and compositions thereof
JP2014508113A (ja) * 2010-12-10 2014-04-03 シンアジャイル コーポレーション 皮下注入可能なレボドパプロドラッグ組成物及び注入方法
US8765189B2 (en) 2011-05-13 2014-07-01 Howmedica Osteonic Corp. Organophosphorous and multivalent metal compound compositions and methods
AU2012301770B8 (en) * 2011-08-31 2017-01-19 Abbvie Inc. Sealing arrangement for syringe
KR102209353B1 (ko) 2013-03-13 2021-01-29 뉴로덤 엘티디 파킨슨 병 치료 방법
EP3065808B1 (fr) * 2013-11-05 2023-08-30 SynAgile Corporation Dispositifs et procédés pour l'administration de médicament continue par la bouche

Also Published As

Publication number Publication date
PH12017501304A1 (en) 2018-02-05
JP2021073186A (ja) 2021-05-13
US20190142777A1 (en) 2019-05-16
KR20170103967A (ko) 2017-09-13
AU2016209420A1 (en) 2017-08-03
IL253487A0 (en) 2017-09-28
CN116036064A (zh) 2023-05-02
WO2016118556A1 (fr) 2016-07-28
US20210046029A1 (en) 2021-02-18
MX2017009325A (es) 2018-02-09
EP4470611A2 (fr) 2024-12-04
JP2018503686A (ja) 2018-02-08
US10117843B2 (en) 2018-11-06
EP3247330A1 (fr) 2017-11-29
AU2016209420B2 (en) 2021-05-20
JP2023058678A (ja) 2023-04-25
US20160206584A1 (en) 2016-07-21
BR112017015613A2 (pt) 2018-03-13
CA2974203A1 (fr) 2016-07-28
SG11201705964YA (en) 2017-08-30
BR112017015613B1 (pt) 2023-11-28
RU2017129375A3 (fr) 2019-08-05
JP2024129122A (ja) 2024-09-26
CN107427463A (zh) 2017-12-01
JP7232235B2 (ja) 2023-03-02
TW201639556A (zh) 2016-11-16
RU2017129375A (ru) 2019-02-21
EP4470611A3 (fr) 2025-02-19

Similar Documents

Publication Publication Date Title
EP3390624A4 (fr) Polypeptides de modification ciblée modifiés et leurs procédés d'utilisation
EP3303634A4 (fr) Variants de cas9 et procédés d'utilisation associés
MA44507A (fr) Récepteurs chimères de flt3 et leurs procédés d'utilisation
EP3377612A4 (fr) Expression fonctionnelle de monooxygénases et procédés d'utilisation
EP3394065A4 (fr) Tétrahydropyranyl-amino-pyrrolopyrimidinone et procédés d'utilisation associés
EP3436048A4 (fr) Néoantigènes et leurs procédés d'utilisation
EP3352774A4 (fr) Compositions de flavonoïdes et procédés d'utilisation
EP3307762A4 (fr) Variants de cas9 rapporteurs et leurs procédés d'utilisation
MA55097A (fr) Oxystérols et leurs procédés d'utilisation
EP3313404A4 (fr) Compositions thérapeutiques, associations et procédés d'utilisation
MA40069A (fr) Molécules de liaison trispécifiques et leurs procédés d'utilisation
EP3271352A4 (fr) Carbamates de pipérazine et procédés de préparation et d'utilisation de ceux-ci
MA54851A (fr) Oxystérols et leurs procédés d'utilisation
MA42409A (fr) Oxystérols et leurs procédés d'utilisation
EP3341027A4 (fr) Complexes de transfection et leurs procédés d'utilisation
EP3314218A4 (fr) Distributeurs de dose mesurée et leurs procédés d'utilisation
EP3368663A4 (fr) Lignées cellulaires exemptes de virus et procédés d'obtention de celles-ci
EP3386927A4 (fr) Compositions polymères et procédés d'utilisation
EP3680331A4 (fr) Protéine cas9 modifiée et utilisation de celle-ci
EP3349851A4 (fr) Polypeptides photosensibles et leurs procédés d'utilisation
LT3554580T (lt) Trans analinės irigacijos prietaisas ir sistema
MA50912A (fr) Inhibiteurs d'acss2 et leurs procédés d'utilisation
EP3635000A4 (fr) Manabodies et procédés d'utilisation
MA50403A (fr) Promédicaments de dantrolène et leurs procédés d'utilisation
EP3350351A4 (fr) Plate-forme de séquençage de capture de virome, procédés de conception et de construction et procédés d'utilisation